Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...
In 2025, Generative AI will prove transformational for drug discovery in the healthcare industry. With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the ...
CAMBRIDGE, Mass., Dec 5, 2024 --- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully closed the ...
Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback